Reviewing IN8bio (NASDAQ:INAB) and Cadrenal Therapeutics (NASDAQ:CVKD)

Cadrenal Therapeutics (NASDAQ:CVKD) and IN8bio (NASDAQ:INAB) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, risk, institutional ownership, valuation, dividends and earnings.

Analyst Recommendations

This is a summary of recent recommendations for Cadrenal Therapeutics and IN8bio, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cadrenal Therapeutics	1	0	1	0	2.00
IN8bio	1	1	1	0	2.00

Cadrenal Therapeutics presently has a consensus price target of $32.00, indicating a potential upside of 347.87%. IN8bio has a consensus price target of $92.00, indicating a potential upside of 4,605.88%. Given IN8bio’s higher probable upside, analysts plainly believe IN8bio is more favorable than Cadrenal Therapeutics.

Institutional and Insider Ownership

7.9% of Cadrenal Therapeutics shares are held by institutional investors. Comparatively, 92.1% of IN8bio shares are held by institutional investors. 26.1% of Cadrenal Therapeutics shares are held by insiders. Comparatively, 15.5% of IN8bio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares Cadrenal Therapeutics and IN8bio”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cadrenal Therapeutics	N/A	N/A	-$10.65 million	($8.01)	-0.89
IN8bio	N/A	N/A	-$30.44 million	($5.45)	-0.36

Cadrenal Therapeutics is trading at a lower price-to-earnings ratio than IN8bio, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Cadrenal Therapeutics has a beta of 1.08, suggesting that its share price is 8% more volatile than the S&P 500. Comparatively, IN8bio has a beta of 0.02, suggesting that its share price is 98% less volatile than the S&P 500.

Profitability

This table compares Cadrenal Therapeutics and IN8bio’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cadrenal Therapeutics	N/A	-279.50%	-204.46%
IN8bio	N/A	-147.21%	-108.63%

Summary

IN8bio beats Cadrenal Therapeutics on 6 of the 9 factors compared between the two stocks.

About Cadrenal Therapeutics

Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. Cadrenal Therapeutics, Inc. was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.

About IN8bio

IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidates include INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation; and INB-400, which is in Phase 2 clinical trial to treat newly diagnosed GBM. It also develops INB-300, INB-410, and INB-500 that are in preclinical Phase for treatment of various solid tumor cancers. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is headquartered in New York, New York.